Headlines about Innospec (NASDAQ:IOSP) have trended somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Innospec earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned headlines about the specialty chemicals company an impact score of 45.6655378295737 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news headlines that may have effected Accern’s scoring:
IOSP opened at $70.70 on Friday. The company has a market cap of $1,740.50, a PE ratio of 15.17 and a beta of 1.03. Innospec has a one year low of $54.10 and a one year high of $74.30. The company has a current ratio of 2.15, a quick ratio of 1.34 and a debt-to-equity ratio of 0.26.
Innospec (NASDAQ:IOSP) last announced its quarterly earnings results on Tuesday, February 13th. The specialty chemicals company reported $1.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.34. The firm had revenue of $353.80 million during the quarter. Innospec had a return on equity of 15.57% and a net margin of 4.73%. equities research analysts predict that Innospec will post 4.3 earnings per share for the current year.
A number of research firms have recently commented on IOSP. BidaskClub raised Innospec from a “sell” rating to a “hold” rating in a research note on Thursday, March 8th. ValuEngine raised Innospec from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. Finally, Zacks Investment Research cut Innospec from a “hold” rating to a “strong sell” rating in a research note on Friday, February 23rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $70.50.
In related news, VP Catherine Hessner sold 1,382 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $68.24, for a total value of $94,307.68. Following the completion of the sale, the vice president now owns 27,518 shares in the company, valued at $1,877,828.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Philip John Boon sold 501 shares of the business’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $67.04, for a total value of $33,587.04. Following the completion of the sale, the vice president now owns 35,439 shares of the company’s stock, valued at approximately $2,375,830.56. The disclosure for this sale can be found here. Insiders sold 12,112 shares of company stock valued at $832,724 in the last quarter. 2.02% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/14/innospec-iosp-getting-somewhat-positive-press-coverage-report-shows.html.
Innospec Inc develops, manufactures, blends, markets, and supplies specialty chemicals for use as fuel additives, ingredients for personal care, home care, agrochemical, mining and other applications, and oilfield chemicals worldwide. It operates through four segments: Fuel Specialties, Performance Chemicals, Oilfield Services, and Octane Additives.
Receive News & Ratings for Innospec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innospec and related companies with MarketBeat.com's FREE daily email newsletter.